Skip to main content

Psoriasis clinical trials at UC Davis

3 research studies open to eligible people

Showing trials for
  • A Study of Experimental Therapy With Nivolumab For Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

    open to eligible people ages 18 years and up

    The purpose of this study is to explore the safety, tolerability and activity of Nivolumab, a PD-1 inhibitor, in cohorts of patients with autoimmune disease. Two cohorts of patients will be enrolled, based on autoimmune disease type. Patients will be screened within 28 days prior to the start of dosing. Eligible patients will be enrolled in either of the two cohorts. Patients will receive treatment every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle. Subjects will be permitted to continue treatment beyond initial RECIST 1.1.

    Portland, Oregon and other locations

  • A Study of Skin Diseases Brought About by Irregular Immune System Response

    “Help researchers learn more about immune cells that contribute to skin disease”

    open to eligible people ages 18-55

    This study is designed to identify the cells of the immune system that cause skin disease such as psoriasis and mycosis fungoides. Blood samples from many patients will be compared in hopes of finding common cells and molecules responsible for skin diseases. Results of this study will increase our knowledge about immune mediated skin disease.

    Sacramento, California

  • Effectiveness and Safety of Experimental Secukinumab Doses in Patients 90kg-or-greater with Severe Chronic Plaque-type Psoriasis

    open to eligible people ages 18 years and up

    Demonstrate superiority of secukinumab high dose over standard dose in heavy body weight subjects with moderate to severe plaque psoriasis.

    Sacramento, California and other locations

Last updated: